肺部免疫与免疫病理学：来自呼吸道合胞病毒的经验教训。
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.
作者信息
Olson Matthew R, Varga Steven M
机构信息
Department of Microbiology, Interdisciplinary Graduate Program in Immunology, 51 Newton Road, 3-532 Bowen Science Building, University of Iowa, Iowa City, IA 52242, USA.
出版信息
Expert Rev Vaccines. 2008 Oct;7(8):1239-55. doi: 10.1586/14760584.7.8.1239.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants and is an important source of morbidity and mortality in the elderly and immunocompromised. This review will discuss the humoral and cellular adaptive immune responses to RSV infection and how these responses are shaped in the immature immune system of the infant and the aged environment of the elderly. Furthermore, we will provide an overview of our current understanding of the role the various arms of the adaptive immune response play in mediating the delicate balance between the successful elimination of the virus from the host and the induction of immunopathology. Efficacious immunization against RSV remains a high priority within the field and we will highlight recent advances made in vaccine design.
摘要
呼吸道合胞病毒（RSV）是婴儿严重呼吸道疾病的主要病因，也是老年人和免疫功能低下者发病和死亡的重要原因。本综述将讨论针对RSV感染的体液和细胞适应性免疫反应，以及这些反应在婴儿未成熟免疫系统和老年人衰老环境中的形成方式。此外，我们将概述目前对适应性免疫反应各分支在介导从宿主体内成功清除病毒与诱导免疫病理之间微妙平衡中所起作用的理解。针对RSV的有效免疫接种仍是该领域的高度优先事项，我们将重点介绍疫苗设计方面的最新进展。
相似文献
1
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.
Expert Rev Vaccines. 2008 Oct;7(8):1239-55. doi: 10.1586/14760584.7.8.1239.
2
Mucosal vaccines against respiratory syncytial virus.
Curr Opin Virol. 2014 Jun;6:78-84. doi: 10.1016/j.coviro.2014.03.009. Epub 2014 Apr 29.
3
Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
J Virol. 2012 Apr;86(8):4505-17. doi: 10.1128/JVI.07091-11. Epub 2012 Feb 1.
4
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.
Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x.
5
Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
Hum Vaccin Immunother. 2014;10(3):615-22. doi: 10.4161/hv.27383. Epub 2013 Dec 10.
6
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
PLoS One. 2011;6(7):e21823. doi: 10.1371/journal.pone.0021823. Epub 2011 Jul 15.
7
Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.
Front Immunol. 2019 Mar 29;10:597. doi: 10.3389/fimmu.2019.00597. eCollection 2019.
8
Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.
Curr Med Chem. 2009;16(34):4609-25. doi: 10.2174/092986709789760724.
9
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.
10
Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
Front Immunol. 2018 Mar 2;9:323. doi: 10.3389/fimmu.2018.00323. eCollection 2018.
引用本文的文献
1
Evaluation of dual pathogen recognition receptor agonists as adjuvants for respiratory syncytial virus - virus-like particles for pulmonary delivery.
Front Immunol. 2025 Mar 17;16:1561297. doi: 10.3389/fimmu.2025.1561297. eCollection 2025.
2
A Brief History of Human Challenge Studies (1900-2021) Emphasising the Virology, Regulatory and Ethical Requirements, Raison D'etre, Ethnography, Selection of Volunteers and Unit Design.
Curr Top Microbiol Immunol. 2024;445:1-32. doi: 10.1007/82_2022_253.
3
Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity.
Vaccines (Basel). 2022 Apr 10;10(4):584. doi: 10.3390/vaccines10040584.
4
A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.
Sci Adv. 2022 Jan 7;8(1):eabh3827. doi: 10.1126/sciadv.abh3827.
5
Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection.
Vaccines (Basel). 2021 Mar 8;9(3):232. doi: 10.3390/vaccines9030232.
6
Progress in the development of virus-like particle vaccines against respiratory viruses.
Expert Rev Vaccines. 2020 Jan;19(1):11-24. doi: 10.1080/14760584.2020.1711053. Epub 2020 Jan 18.
7
Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Microbiol Immunol. 2020 Jan;64(1):33-51. doi: 10.1111/1348-0421.12754. Epub 2019 Nov 18.
8
Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform.
Immune Netw. 2019 May 27;19(3):e18. doi: 10.4110/in.2019.19.e18. eCollection 2019 Jun.
9
The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
Antiviral Res. 2019 Aug;168:100-108. doi: 10.1016/j.antiviral.2019.05.011. Epub 2019 May 28.
10
Simultaneous Administration of Recombinant Measles Viruses Expressing Respiratory Syncytial Virus Fusion (F) and Nucleo (N) Proteins Induced Humoral and Cellular Immune Responses in Cotton Rats.
Vaccines (Basel). 2019 Mar 4;7(1):27. doi: 10.3390/vaccines7010027.
本文引用的文献
1
CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy.
Eur J Immunol. 2008 Aug;38(8):2168-79. doi: 10.1002/eji.200838155.
2
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.
J Leukoc Biol. 2008 Sep;84(3):748-59. doi: 10.1189/jlb.0907621. Epub 2008 Jun 2.
3
Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain.
Protein Sci. 2008 May;17(5):813-20. doi: 10.1110/ps.073366208. Epub 2008 Mar 27.
4
Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus.
J Exp Med. 2008 Mar 17;205(3):711-23. doi: 10.1084/jem.20071140. Epub 2008 Mar 10.
5
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development.
J Virol. 2008 May;82(9):4441-8. doi: 10.1128/JVI.02541-07. Epub 2008 Feb 20.
6
IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease.
J Immunol. 2008 Feb 15;180(4):2376-84. doi: 10.4049/jimmunol.180.4.2376.
7
Newcastle disease virus as a vaccine vector for humans.
Curr Opin Mol Ther. 2008 Feb;10(1):46-55.
8
Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus.
J Virol. 2008 Mar;82(5):2196-207. doi: 10.1128/JVI.01949-07. Epub 2007 Dec 19.
9
Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.
J Virol. 2008 Mar;82(5):2350-7. doi: 10.1128/JVI.02372-07. Epub 2007 Dec 19.
10
CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections.
J Immunol. 2007 Dec 15;179(12):8410-7. doi: 10.4049/jimmunol.179.12.8410.
Zotero 插件